Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN IN DEXTROSE 5% vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina,Acute myocardial infarction (to reduce preload and afterload),Heart failure (off-label use for acute decompensated heart failure),Hypertensive crisis (off-label use for severe hypertension)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Extensively metabolized in the liver by glutathione-dependent organic nitrate reductase, and to a lesser extent via cytochrome P450 (CYP3A4). Primary metabolite is 1,2-glyceryl dinitrate (active).
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
~60% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~28% bound to albumin.
Vd: 0.3 L/kg; reflects distribution into vascular smooth muscle and minimal tissue penetration.
2–4 L/kg, indicating extensive tissue distribution.
Intravenous: 100%; sublingual: ~40% (first-pass hepatic metabolism); oral: <10% due to extensive first-pass effect.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No specific dose adjustment required for renal impairment; monitor for volume status and hypotension.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh Class A: No adjustment. Class B: Reduce initial dose by 50%. Class C: Avoid use or reduce initial dose by 75%.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not FDA-approved for pediatric use. Limited data: IV infusion 0.25-0.5 mcg/kg/min, titrate to effect; max 5 mcg/kg/min.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Lower initial doses recommended due to increased sensitivity; start at 5 mcg/min IV or 0.3 mg sublingual; monitor for hypotension.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
NOT available in this formulation. Nitroglycerin products do not carry a black box warning.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension (severe hypotension may occur, especially with hypovolemia),Bradycardia and paradoxical tachycardia,Increased intracranial pressure (use cautiously in head trauma or intracranial hemorrhage),Tolerance to nitrates with prolonged use (intermittent dosing recommended),Methemoglobinemia (rare, risk with high doses or prolonged infusion),Drug interactions with phosphodiesterase inhibitors (e.g., sildenafil) causing severe hypotension
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure,Constrictive pericarditis or cardiac tamponade,Severe hypotension (systolic BP < 90 mm Hg),Acute myocardial infarction with right ventricular involvement,Obstructive cardiomyopathy (relative contraindication)
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol; may cause severe hypotension and reflex tachycardia. No other significant food interactions.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human data. However, animal studies are insufficient to rule out risk. During the second and third trimesters, nitroglycerin is used for tocolysis and management of hypertensive emergencies without documented fetal harm, but potential for maternal hypotension leading to reduced uteroplacental perfusion exists. Overall, FDA assigns category C (risk cannot be ruled out).
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Nitroglycerin is excreted into breast milk in minimal amounts; the M/P ratio is not established. Concentrations are likely too low to cause adverse effects in the nursing infant. Based on limited data, nitroglycerin is considered compatible with breastfeeding, but caution is recommended, especially in infants with cardiovascular instability.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered drug metabolism) may necessitate dose titration to effect. No standard dose adjustment is defined; clinicians should initiate at low doses and titrate based on maternal blood pressure and uterine perfusion. The typical starting dose of 5 mcg/min intravenous is appropriate, with incremental increases guided by clinical response. Avoid bolus doses to prevent hypotension.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
For IV nitroglycerin in D5W, use non-PVC tubing (light-sensitive) and inline filter; avoid abrupt discontinuation to prevent rebound hypertension; titrate to chest pain relief or hemodynamic parameters; monitor for hypotension and bradycardia; tolerance may develop after 24 hours of continuous infusion.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Report any chest pain, severe headache, or dizziness immediately.,Avoid alcohol consumption while on this medication.,Do not stop infusion suddenly without medical supervision.,Remain lying down if dizzy or lightheaded.,Inform all healthcare providers of nitroglycerin use.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN IN DEXTROSE 5% vs ISORDIL, answered by our medical review team.
NITROGLYCERIN IN DEXTROSE 5% is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN IN DEXTROSE 5% and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN IN DEXTROSE 5% is: Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN IN DEXTROSE 5% and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN IN DEXTROSE 5% is classified as Category C. Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.